Elbit Medical Technologies Ltd

As of June 30, 2021, Elbit Medical Technologies Ltd has 92.79M shares outstanding.

As of June 30, 2021, Elbit Medical Technologies Ltd trades at a trailing price-to-earnings ratio of 48.73.

These figures are as of June 30, 2021. Elbit Medical Technologies Ltd trades at an EV/FCF ratio of 31.31, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2021, Elbit Medical Technologies Ltd maintains a current ratio of 1.21, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 78.63, indicating elevated leverage, while an interest coverage ratio of -0.16 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2021. Return on invested capital (ROIC) is negative at -0.65, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 1.25, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is negative at -40.87, pointing to unprofitable operations over the period.

These figures cover the twelve months ended June 30, 2021. Free cash flow yield is negative at -1.32: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 32.03, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Elbit Medical Technologies Ltd shareholders.

Elbit Medical Technologies Ltd's most recent stock split took place on February 8, 2018 with a 8:1 split ratio.

As of June 30, 2021, Elbit Medical Technologies Ltd has an Altman Z-Score of 0.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.